The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-γ/α agonist-induced edema in type 2 diabetic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 9, 2006, Pages 3446-3450

  Hansen, Lars ^a,e   Ekstrøm, Claus T ^d   Tabanera Y Palacios, René ^a   Anant, Madan ^c   Wassermann, Karsten ^b   Reinhardt, Rickey R ^b  

^a NOVO NORDISK A S   (Denmark)

^b NOVO NORDISK INC   (United States)

^c Clinical Data Inc   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; RAGAGLITAZAR; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; FLUID RETENTION; GENE; HAPLOTYPE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PPARG GENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 33748742987     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-0590     Document Type: Article

References (18)

1. Yki-Järvinen H 2004 Thiazolidinediones. N Engl J Med 351:1106-1118
2. 2003 A consensus statement from the American Heart Association and American Diabetes Association: thiazolidinediones use, fluid retention, and congestive heart failure. Circulation 108:2941-2948
3. Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner H-R, Burnier M 2003 Effects of the peroxisome proliferator-activated receptor-γ agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 89:1140-1145
4. Karalieddde J, Starkei GM, Lorand DF, Stewart MG, Viberti G 2005 Management of rosiglitazone related fluid retention. Diabetes 54(Suppl 1):A20
5. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T 2005 Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 102:9406-9411
6. Guan YF, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD 2005 Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENAC-mediated renal salt absorption. Nat Med 11:861-866
7. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J 1998 A Pro12Ala substitution in PPARγ2 is associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287
8. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl M-C, Nemesh J, Lane CR, Schaffner SE, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES 2000 The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics 26:76-80
9. Barroso I, Gurnell M, Crowley VEF, Agostini M, Schwabel JW, Soos MA, Maslen GLI, Williams TDM, Lewis H, Schafer AJ, Chatterjee VKK, O'Rahilly S 1999 Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883
10. Agostini M, Gurnell M, Savage DB, Wood EM, Smith AG, Rajanayagam O, Garnes KT, Levinson SH, Xu HE, Schwabe JW, Willson TM, O'Rahilly S, Chatterjee VK 2004 Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor γ. Endocrinology 145:1527-1538
11. Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M, Reinhardt RR 2004 Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects. Diabetes Care 27:1324-1329
12. Karraliedde J, Hider A, Donaldson J, Stewart M, Viberti G2005 Predictors of rosiglitazone induced fluid retention. Diabetologia 48(Suppl 1):A281; 773
13. van Wijk JP, Cabezas MC, Joven J, Rabelink TJ, Koning EJ 2005 Effects of rosiglitazone on postprandial leucocytes and cytokines in type 2 diabetes. Atherosclerosis 186:152-159
14. Meirhaeghe A, Cottel D, Amouyel P, Dallongeville J 2005 Association between peroxisome proliferator-activated receptor γ haplotypes and the metabolic syndrome in French men and women. Diabetes 54:3043-3048
15. Lyssenko V, Almgren P, Anevski D, Orho-Melander M, Sjögren M, Saloranta C, Tuomi I, Groop L 2005 The Botnia Study Group: genetic prediction of future type 2 diabetes. PLOS Med 2:1299-1308
16. Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM 2005 Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction. Diabetes Care 28:1680-1689
17. Dormandy JA, Charbonnel B, Eckland DJA, on behalf of the PROactive investigators 2005 Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 366:1279-1289
18. Semenkovich CF 2005 TZDs and diabetes: testing the waters. Nat Med 11:822-824